ClinicalTrials.gg
Not yet recruitingNCT07736781Updated Jul 30, 2026

Research Title: Long Term Functional Outcome of a Single Hyaluronic Acid Injection in Improving Symptoms and Function in Patients With Knee Osteoarthritis - A Single-Arm Open-Label Study (DIART ONE).

A Phase 3 interventional study of Hyaluronic Acid (HA) in Osteo Arthritis of the Knee, sponsored by Universiti Sains Malaysia. Not yet recruiting at 1 site in Malaysia. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Universiti Sains Malaysia · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee — 4 open to participants now, 4 under way, 2 of them phase 3. Hyaluronic Acid · Osteoarthritis, Knee.

Planned enrollment
8th of 18
62 · median 55
Started
2026
with 2 others
Phase 3
3 of 18
1 open now
Registered
18th of 18
by date

Among the 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee, this one is the 8th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 3, and was the 18th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

4 of the 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Hyaluronic Acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

This study aims to evaluate the effectiveness of a single HA injection in improving pain, function, and quality of life in patients with knee OA over a 12-month period. By focusing on a single-arm open-label design, this study will provide practical insights into the real-world application of this treatment approach.

Read the detailed description

Single-arm, open-label studies play a crucial role in the clinical research ecosystem. These studies are often conducted to:

  1. Assess the performance of a novel HA formulation (e.g., different molecular weights, cross-linking technologies).
  2. Gather "real-world" evidence in broader, less restrictive patient populations.
  3. Provide preliminary data to support the design of larger, more expensive RCTs.
  4. Investigate outcomes in specific patient subpopulations (e.g., severe OA, different age groups).

1. To compare mean differences VAS Score 0,1,3,6,12 months. 2. To study comparison WOMACS mean differences. 3. To document the safety and tolerability of a single HA injection in a real-world clinical setting.

03

Conditions studied

  • Osteo Arthritis of the Knee

Keywords

  • OSTEOARTHRITIS OF THE KNEE , DIART ONE
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

i. Adults aged 40-75 years with a clinical and radiographic diagnosis of knee OA (Kellgren-Lawrence grade II-III).

ii. Persistent knee pain (≥4 on a 10-point Visual Analogue Scale [VAS]) for at least 3 months.

iii. Failure to achieve adequate pain relief with conservative treatments (e.g., NSAIDs, physical therapy).

iv. Willingness to provide and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

i. Severe OA (Kellgren-Lawrence grade IV). ii. History of knee surgery or HA injection within the past 6 months. iii. Inflammatory arthritis (e.g., rheumatoid arthritis, gout). iv. to HA injections (e.g., infection, allergy to HA products).

v. Significant comorbidities that may interfere with study participation (e.g., uncontrolled diabetes, morbid obesity, severe cardiovascular disease).

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    DIART ONE

    Treatment Arm will receive a single HA injection to reduce pain and improving knee function in patients with knee OA over 12 months. Outcomes will be assessed, including pain (VAS), function (WOMAC), and safety ( adverse events)

    Drug: Hyaluronic Acid (HA)

Interventions

06

What researchers measure

Primary outcomes

  1. Functional assessment of patient with osteoarthritic knee included in this study

    WOMAC osteoarthritis index is going to be used to assess the functionality of the patient with osteoarthritic knee, included in the study. Assessment is done 0, 1, 3, 6,12 months

    Time frame: 1 YEAR

  2. Assessment of pain score in knee osteoarthritic patient

    The outcomes is measured using visual analogue score (VAS) for pain intensity assessment at 0, 1, 3, 6,12 months.

    Time frame: 1YEAR

07

Study locations

1 site
08

References and documents

Publications

  • Suppan VKL, Tew MM, Muthusamy H, Voon JM, Ramli NAMN, Phuah ASJ, Murugaiah D. Long-term functional and clinical outcomes of intraarticular double-cross-linked high molecular weight hyaluronic acid (Crespine Gel Plus) injection in knee osteoarthritis: a one year prospective study. BMC Musculoskelet Disord. 2026 Feb 9;27(1):209. doi: 10.1186/s12891-026-09588-1. PubMed 41664047 ↗

Related links

Individual participant data

Plan to share: Undecided — To protect participant personal data

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

Of 36 non-industry phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 24 months is below that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2026
First posted
Jul 30, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Aug 30, 2028
CompletionEst.
Aug 30, 2029
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07736781
Collaborators
Hospital Universiti Sains Malaysia
Responsible party
Amran Ahmed Shokri (PROFESSOR (DR), Universiti Sains Malaysia) — Principal investigator
First posted
Jul 30, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Aug 30, 2028 (estimated)
Completion
Aug 30, 2029 (estimated)
Last update
Jul 30, 2026

Study contacts

SASSIDHAREN PONNALAGU, MEDICAL DEGREE
Contact
sassidharen6@gmail.com
+60102922046
Amran Prof. Dr A Shokri, master in orthopedics
Contact
amrankb@usm.my
+60 12-900 9272
AMRAN AHMED SHOKRI, MASTER IN ORTHOPEDIC
principal investigator · Universiti Sains Malaysia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronic Acid

Start the discussion